TABLE III.
Most common treatment used for metastatic triple-negative breast cancer
| Chemo Regimen | First-line (%; n=46) | Second-line (%; n=44) |
|---|---|---|
| Docetaxel q3w, Paclitaxel qw, Paclitaxel q3w | 70 | 10 |
| Nab-paclitaxel q3w | 0 | 0 |
| Nab-paclitaxel qw | 7 | 4 |
| Platinum-based chemo | 13 | 28 |
| Single agent capecitabine | 4 | 38 |
| Other single agent chemo | 2 | 4 |
| Anthracyclines | 5 | 12 |
| CMF | 0 | 2 |
| Doublet chemo (e.g. capecitabine + docetaxel) | 0 | 2 |
| Chemo + bevacizumab | 0 | 0 |
CMF = cyclophosphamide, methotrexate, fluorouracil; Chemo = chemotherapy; n = number of patients; qw = weekly; q3w = every three weeks